Fig. 5: Prognostic impact of genomic AML classes and clinical characteristics in FLT3-mutated AML. | Leukemia

Fig. 5: Prognostic impact of genomic AML classes and clinical characteristics in FLT3-mutated AML.

From: Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

Fig. 5

Cox proportional hazard model for prognostic impact of genomic AML classes and clinical features on (A) overall and (B) event-free survival in the cohort of 451 of 475 patients, in which subcategorization into genomic AML classes was possible. A hazard ratio of >1 indicates a higher and a hazard ratio of <1 a lower hazard of death or event, respectively. The NPM1 class was used as reference group, allogeneic HCT in first remission as time-dependent variable. ECOG Eastern Cooperative Oncology Group, HCT hematopoietic cell transplantation, WBC white blood cell count.

Back to article page